To further validate microglial activation in response to BCM, microglia were treated with BCM and immunostained with phenotypic markers of disease associated microglia (TREM-2) and M1 type microglia (CD86) (Figure 2b). The gene discussed is CD86; the disease is blue cone monochromacy.